Cover Image
Market Research Report
Product code 
1103056

Cell Surface Markers

Published: | Global Industry Analysts, Inc. | 683 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cell Surface Markers
Published: July 1, 2022
Global Industry Analysts, Inc.
Content info: 683 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Cell Surface Markers Market to Reach $1 Billion by 2026

Cell surface markers or cell surface antigens are special carbohydrates or proteins present on cell membrane and can be exploited for identification and classification of cells. A growing number of healthcare facilities including hospitals, doctor`s offices, and diagnostic centers, as well as research entities including pharmaceutical laboratories, independent research institutions, academic/university research programs, and contract research organizations are prioritizing cell surface markers identification in diagnosis as well as research applications. Growth in the global market is set to be fueled by increasing adoption of sophisticated analytical technologies and in-vitro diagnostic tools as a result of ongoing efforts to reduce disease and to reduce healthcare burden. The market is also benefitting from rising application of stem cell technology, and efforts to reduce disease diagnosis costs. The emergence of new therapies to target liver cancer stem cells is expected to improve overall efficacy of traditional radiotherapy and chemotherapy procedures intended to treat liver cancer. One of the noteworthy developments in this direction is the identification of an ATP-competitive mTOR inhibitor, INK128, which holds potential to suppress CD44+, a liver cancer stem cell surface marker, along with sorafenib-insensitive hepatocellular carcinoma in-vivo and in-vitro.

Amid the COVID-19 crisis, the global market for Cell Surface Markers estimated at US$749.1 Million in the year 2022, is projected to reach a revised size of US$1 Billion by 2026, growing at a CAGR of 8.9% over the analysis period. Antibodies, one of the segments analyzed in the report, is projected to grow at a 10.7% CAGR to reach US$703.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the PCR Arrays segment is readjusted to a revised 6.4% CAGR for the next 7-year period. This segment currently accounts for a 43.8% share of the global Cell Surface Markers market.

The U.S. Market is Estimated at $342.7 Million in 2022, While China is Forecast to Reach $85.5 Million by 2026

The Cell Surface Markers market in the U.S. is estimated at US$342.7 Million in the year 2022. The country currently accounts for a 45.37% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$85.5 Million in the year 2026 trailing a CAGR of 10.8% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR while Rest of European market (as defined in the study) will reach US$93.8 Million by the end of the analysis period. The US, followed by Europe, leads the global cell surface markers market, and claimed a commanding share, owing to the presence of prominent players, strong focus on R&D and extensive customer base. The regional market growth is augmented by rising use of cell surface markers in personalized medicine and drug discovery. Growth in North America region is attributed to the presence of prominent players, strong focus on R&D and extensive customer base. The regional market growth is augmented by rising use of cell surface markers in personalized medicine and drug discovery. The market growth is also facilitated by rising cases of chronic medical conditions, mainly cancer, and the resulting requirement of effective diagnostic capabilities. Growing healthcare and research expenditure, increased uptake of medical devices, and move towards laboratory automation are the major growth drivers fueling market expansion in developing regions.

Select Competitors (Total 70 Featured) -

  • Abbott Laboratories, Inc.
  • BD Biosciences
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols, S.A.
  • Immucor, Inc.
  • Nihon Kohden Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MCP-7908

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Cell Surface Markers: A Prelude
    • Researchers Indentify Over-Expression of CD8 Marker on Cytotoxic T-Cells in Patients with COVID-19 Infection
    • Cell Surface Markers - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Hospitals Eye on CRP as Diagnostic Marker to Distinguish Common Cold from COVID-19
    • Robust Demand for Analytical Techniques and Focus on Timely Diagnosis Drive Growth of Global Cell Surface Markers Market
    • Research Dominates Cell Surface Markers Market, Clinical Diagnostics to Exhibit Fastest Growth
    • Flow Cytometers Lead the Cell Surface Markers Market
    • T and B Cells Dominate the Market
    • Developed Regions: Major Revenue Contributors
    • Developing Regions Drive Future Growth
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
    • Innovations & Advancements
  • 3. MARKET TRENDS & DRIVERS
    • High Uptake in Drug Discovery Applications Widens Market Prospects
    • Role of Flow Cytometry in Cell Line Development
    • Multicolor Flow Cytometry Offers Perfect Option to Understand B-Cell Development
    • Hematology Analyzers Gain Traction in Cell Surface Marker Identification
    • Growing Hematology Analyzers Market Witnesses Steady Growth
    • Key Technology Trends in Hematology Analyzers Market
    • Rising Cancer Incidence Worldwide Spurs Demand For Cell Surface Markers
    • Select Markers for Cancer Stem Cell Identification
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Use of CD Markers in Identification and Classification of Leukocyte Populations
    • Most Common CD markers for Flow Cytometry
    • Growing Significance of Personalized Medicine: An Opportunity for Cell Surface Markers
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
    • RNA Sequencing Emerges as Potential Approach to Identify Cell Surface Markers for Enabling Precision Medicine
    • Cell Surface Markers Grows Significantly in Stem Cell Research
    • Select Cell Surface Markers Used in Stem Cell Identification and Characterization
    • Hematopoietic Stem Cell Markers Provide Useful Insights into Hematopoiesis
    • Genetically Engineered CAR T-Cells Present Potential Weapon to Eliminate Cancer Stem Cells and Prevent Recurrence of Cancer
    • Key Models
    • CSC Population & Noteworthy Markers
  • ALDH
    • CD44
    • CD90
    • CD133
    • EpCAM & EGFR
    • Immunotherapy Targets Natural Killer Cells to Offer Hope for Cancer Patients
    • Cell Surface Markers Identification Assumes Critical Importance amid Growing Prevalence of Chronic Diseases
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Aging Demographics Present Opportunities for Cell Surface Markers
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Clinical Management of Autoimmune Diseases
    • Flow Cytometry Remains the Gold Standard in HIV Testing and Monitoring
    • Global HIV Prevalence: 2019
    • Increased Emphasis on Lab Automation Builds Opportunities
    • Increasing Investments on Advanced Equipment in Disease Diagnosis Underpin Volume Growth
    • Growing Focus on Data Management in Research Programs Extends Opportunities
    • Rat Markers
    • Lineage and Antibodies Specific Rat Markers
    • Commonly Used Key Rat Markers by Antibodies and Research Area/Target Cell
    • New Anti-Rat Antibodies Products Expand Scope of Applications
    • ED Clone Anti-Rat Antibodies by Marker and Cell Type
    • Rat Flow Cytometry Panels
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Cell Surface Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 7: World Recent Past, Current & Future Analysis for PCR Arrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for PCR Arrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for PCR Arrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 10: World Recent Past, Current & Future Analysis for T Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for T Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for T Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 13: World Recent Past, Current & Future Analysis for B Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for B Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for B Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 16: World Recent Past, Current & Future Analysis for NK Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for NK Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for NK Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 19: World Recent Past, Current & Future Analysis for Monocyte Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Monocyte Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Monocyte Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 25: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 28: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 31: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 34: World Recent Past, Current & Future Analysis for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Hospitals & Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 37: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Largest Market for Cell Surface Markers
    • Rising Cancer Cases Spur Growth in Cell Surface Markers Market
    • Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
    • Market Benefits from Growing Funding for Stem Cell Research
    • Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 40: USA Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 43: USA Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 46: USA Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 49: USA Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • CANADA
    • High Focus on Improving Healthcare Augurs Well for Market Growth
    • Number of New Cancer Cases in Canada: 2019
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 55: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Canada 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 58: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 61: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Canada Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Canada 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • JAPAN
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Japan 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 67: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Japan Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Japan 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 70: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Japan Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Japan 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 73: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Japan Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Japan 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • CHINA
    • Increasing Cancer Research to Drive Cell Surface Markers Market
    • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 76: China Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: China Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: China 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 79: China Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: China Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: China 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 82: China Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: China Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: China 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 85: China Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: China Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: China 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • EUROPE
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • TABLE 88: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 89: Europe Historic Review for Cell Surface Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Europe 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
    • TABLE 91: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Europe Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Europe 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 94: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Europe Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Europe 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 97: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Europe Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Europe 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 100: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Europe Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Europe 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • FRANCE
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 103: France Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: France Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: France 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 106: France Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: France Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: France 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 109: France Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: France Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: France 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 112: France Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: France Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: France 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • GERMANY
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 115: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Germany Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Germany 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 118: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Germany Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Germany 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 121: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Germany Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Germany 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 124: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Germany Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Germany 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • ITALY
    • TABLE 127: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Italy Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Italy 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 130: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Italy Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Italy 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 133: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Italy Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Italy 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 136: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Italy Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Italy 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • UNITED KINGDOM
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 139: UK Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: UK Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: UK 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 142: UK Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: UK Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: UK 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 145: UK Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: UK Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: UK 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 148: UK Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: UK Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: UK 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • SPAIN
    • TABLE 151: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Spain Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Spain 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 154: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Spain Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Spain 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 157: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Spain Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Spain 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 160: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Spain Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Spain 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • RUSSIA
    • TABLE 163: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Russia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Russia 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 166: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Russia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Russia 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 169: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Russia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Russia 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 172: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Russia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Russia 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF EUROPE
    • TABLE 175: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Rest of Europe Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Rest of Europe 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 178: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Rest of Europe Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Rest of Europe 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 181: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Rest of Europe Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Rest of Europe 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 184: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of Europe Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of Europe 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • ASIA-PACIFIC
    • Increased Cancer Research to Drive the Market for Cell Surface Markers
    • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 187: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 188: Asia-Pacific Historic Review for Cell Surface Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
    • TABLE 190: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Asia-Pacific Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 193: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Asia-Pacific Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 196: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Asia-Pacific Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Asia-Pacific 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 199: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Asia-Pacific Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Asia-Pacific 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • AUSTRALIA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
    • TABLE 202: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Australia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Australia 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 205: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Australia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Australia 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 208: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Australia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Australia 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 211: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Australia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Australia 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • INDIA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
    • TABLE 214: India Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: India Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: India 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 217: India Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: India Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: India 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 220: India Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: India Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: India 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 223: India Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: India Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: India 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
    • India Eyes on RT-LAMP Kits to Ramp up COVID-19 Testing Capacity
    • Molecular Diagnostic Market in India to Witness Significant Growth
    • Growth Drivers in a Nut Shell
  • SOUTH KOREA
    • TABLE 226: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: South Korea Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: South Korea 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 229: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: South Korea Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: South Korea 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 232: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: South Korea Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: South Korea 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 235: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: South Korea Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: South Korea 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 238: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 241: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 244: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 247: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Rest of Asia-Pacific Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: Rest of Asia-Pacific 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • LATIN AMERICA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
    • TABLE 250: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 251: Latin America Historic Review for Cell Surface Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Latin America 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
    • TABLE 253: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Latin America Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Latin America 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 256: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Latin America Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Latin America 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 259: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Latin America Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Latin America 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 262: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Latin America Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Latin America 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • ARGENTINA
    • TABLE 265: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Argentina Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Argentina 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 268: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Argentina Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Argentina 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 271: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Argentina Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Argentina 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 274: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Argentina Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Argentina 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • BRAZIL
    • TABLE 277: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Brazil Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: Brazil 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 280: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Brazil Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: Brazil 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 283: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Brazil Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: Brazil 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 286: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Brazil Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: Brazil 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • MEXICO
    • TABLE 289: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Mexico Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: Mexico 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 292: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Mexico Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Mexico 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 295: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Mexico Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Mexico 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 298: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Mexico Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Mexico 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF LATIN AMERICA
    • TABLE 301: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Rest of Latin America Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Rest of Latin America 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 304: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Rest of Latin America Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 306: Rest of Latin America 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 307: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Rest of Latin America Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 309: Rest of Latin America 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 310: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Rest of Latin America Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 312: Rest of Latin America 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • MIDDLE EAST
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
    • TABLE 313: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 314: Middle East Historic Review for Cell Surface Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 315: Middle East 15-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
    • TABLE 316: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 317: Middle East Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 318: Middle East 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 319: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 320: Middle East Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 321: Middle East 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 322: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 323: Middle East Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 324: Middle East 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 325: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 326: Middle East Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 327: Middle East 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • IRAN
    • TABLE 328: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 329: Iran Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 330: Iran 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 331: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 332: Iran Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 333: Iran 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 334: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 335: Iran Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 336: Iran 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 337: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 338: Iran Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 339: Iran 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • ISRAEL
    • TABLE 340: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 341: Israel Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 342: Israel 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 343: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 344: Israel Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 345: Israel 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 346: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 347: Israel Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 348: Israel 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 349: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 350: Israel Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 351: Israel 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • SAUDI ARABIA
    • TABLE 352: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 353: Saudi Arabia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 354: Saudi Arabia 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 355: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 356: Saudi Arabia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 357: Saudi Arabia 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 358: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 359: Saudi Arabia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 360: Saudi Arabia 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 361: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 362: Saudi Arabia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 363: Saudi Arabia 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 364: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 365: UAE Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 366: UAE 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 367: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 368: UAE Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 369: UAE 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 370: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 371: UAE Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 372: UAE 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 373: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 374: UAE Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 375: UAE 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF MIDDLE EAST
    • TABLE 376: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 377: Rest of Middle East Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 378: Rest of Middle East 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 379: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 380: Rest of Middle East Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 381: Rest of Middle East 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 382: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 383: Rest of Middle East Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 384: Rest of Middle East 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 385: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 386: Rest of Middle East Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 387: Rest of Middle East 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027
  • AFRICA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
    • TABLE 388: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 389: Africa Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 390: Africa 15-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2012, 2021 & 2027
    • TABLE 391: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 392: Africa Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 393: Africa 15-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2012, 2021 & 2027
    • TABLE 394: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 395: Africa Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 396: Africa 15-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2012, 2021 & 2027
    • TABLE 397: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 398: Africa Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 399: Africa 15-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 70